BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -
The presentations will be made this afternoon in New Orleans during the session "Progress in Antifungal Therapy and Prevention" at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
NeXstar Pharmaceuticals and its U.S. development and marketing partner Fujisawa USA have decided to include the data from these studies in its U.S. New Drug Application for AmBisome. The two companies expect to complete the NDA filing within the next several weeks.
In the first presentation, A.C.A.P. Leenders, M.D., of the University Hospital Rotterdam, in The Netherlands, will describe the results of a study in which AmBisome was compared to amphotericin B as a treatment for cryptococcal meningitis in HIV-infected patients. Cryptococcal meningitis is a potentially life-threatening infection of the lining that surrounds the brain and of the cerebral spinal fluid (CSF).
In the paper to be presented, the investigators conclude that "[AmBisome] will sterilize the CSF significantly earlier than 0.7 mg/kg [of amphotericin B], that it has at least equal clinical efficacy and a significantly lower rate of nephrotoxicity when used for the treatment of cryptococcal meningitis in HIV infected patients." The mean time to sterilization of the CSF was 14 days for AmBisome, compared to more than 21 days for amphotericin B.
In the second presentation, Michael Ellis, M.D., a member of the European Organisation for the Research and Treatment of Cancer (EORTC), will detail the results of a randomized, multi-center study of low- and high-dose AmBisome therapy in the treatment of invasive aspergillosis. In this study of 119 cancer patients with impaired immune systems, the investigators found that treatment with low-dose AmBisome for a median of 20 days produced a response of 68 percent. In a separate talk at the same session on antifungal therapy, a team of U.S. investigators will present data from a multi-center study showing that the response rate for conventional amphotericin B therapy of invasive aspergillosis was 24 percent.
NeXstar Pharmaceuticals, Inc. is an integrated pharmaceutical company engaged in the discovery, development, manufacturing and marketing of products to treat life-threatening diseases. The Company currently markets two drugs, AmBisome and DaunoXome. The Company has headquarters in Boulder, Colorado; research, development and manufacturing facilities in San Dimas, California; Antwerp, Belgium; Lakewood, Colorado, and Boulder; and marketing subsidiaries worldwide.
NOTE TO EDITORS: This press release is available on our Web site at http://www.nexstar.com/Press_Releases/PR96.htm. After viewing the press release at this site you can save it as a text file for further use.
CONTACT: NeXstar Pharmaceuticals, Boulder, Colo. Joseph Alper, 303/546-7717 Katy Doherty, 303/546-7889 http://www.nexstar.com
Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
960917
BW960912
Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .